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Abstract: Botulinum toxin type A treatment is the foundation of minimally invasive aesthetic 
facial procedures. Clinicians and their patients recognize the important role, both negative and 
positive, that facial expression, particularly the glabellar frown lines, plays in self-perception, 
emotional well-being, and perception by others. This article provides up-to-date information 
on fundamental properties and mechanisms of action of the major approved formulations of 
botulinum toxin type A, summarizes recent changes in naming conventions (nonproprietary 
names) mandated by the United States Food and Drug Administration, and describes the reasons 
for these changes. The request for these changes provides recognition that formulations of botu-
linum toxins (eg, onabotulinumtoxinA and abobotulinumtoxinA) are not interchangeable and 
that dosing recommendations cannot be based on any one single conversion ratio. The extensive 
safety, tolerability, and efficacy data are summarized in detail, including the patient-reported 
outcomes that contribute to overall patient satisfaction and probability treatment continuation. 
Based on this in-depth review, the authors conclude that botulinum toxin type A treatment 
remains a cornerstone of facial aesthetic treatments, and clinicians must realize that techniques 
and dosing from one formulation cannot be applied to others, that each patient should undergo 
a full aesthetic evaluation, and that products and procedures must be selected in the context of 
individual needs and goals.
Keywords: onabotulinumtoxinA, botulinum toxin type A, cosmetic, glabellar, patient 
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Moderate to severe glabellar lines: the rationale  
for treatment
Perhaps Shakespeare’s oft-quoted “There’s no art to find the mind’s construction in 
the face” (William Shakespeare. The Tragedy of Macbeth; Act I, Scene IV) might 
be amended to note that, although no simple art or science can determine the mind’s 
construction from the face, facial expressions play complex and integral roles in inter-
personal interactions and communication, self-perception and perception by others, 
and mood and emotional experience.1–11
Although researchers do not all agree that an individual’s state of mind or emotion 
can be derived accurately from study of their facial expressions, the seminal work of 
Paul Ekman in the mid-1960s stimulated a wealth of research into the interpretation of 
facial expressions and the existence of feedback loops between emotional experience 
and expression, a concept attributed initially to Charles Darwin.5,10 Briefly, this point 
of view hypothesizes that both negative and positive feelings can be modulated by the 
contraction of underlying facial musculature such as the zygomaticus. A number of Clinical Interventions in Aging 2010:5 102
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studies have provided evidence in support of this hypothesis.5 
Recently, a small observational study indicated that patients 
who received botulinum toxin treatment of frown lines 
exhibited significantly improved mood.2 In contrast, the 
control group of patients who had received other minimally 
invasive cosmetic procedures or botulinum toxin treatment 
of crow’s feet showed no such changes. Another small pilot 
study suggested that treatment of frown lines with botulinum 
toxin could help alleviate depression.12 These findings offer 
intriguing directions for larger, more systematic research.
A brief history of turning back time  
with botulinum toxins
Individuals have sought to improve their appearance throughout 
history and across virtually all cultures, quite possibly as long 
as our species has existed.13 Today’s technology has made avail-
able an increasing array of options, both surgical and minimally 
invasive, to meet these desires and to maintain a more youthful 
appearance. Botulinum toxins have formed the foundation 
of minimally invasive aesthetic facial treatments, beginning 
with their use to smooth glabellar frown lines and expanding 
to include other facial areas as well as combination use with 
other minimally invasive agents and procedures.
The observation that botulinum toxin smoothed facial 
lines when used therapeutically led researchers to study 
the toxin’s effect on glabellar frown lines. In 1992, the first 
published aesthetic study on botulinum toxin established that 
botulinum toxin type A safely and effectively diminished 
the appearance of glabellar lines.14 Additionally, large-
scale, randomized, controlled trials documented safety and 
efficacy, leading to the approval by the United States Food 
and Drug Administration (FDA) of the first botulinum toxin 
for cosmetic use in 2002.15 Recently, the FDA approved 
one additional botulinum toxin type A for cosmetic use.16 
Worldwide, these two formulations are the main neurotoxins 
currently approved by various regulatory authorities for the 
treatment of moderate to severe glabellar lines, although 
other type A formulations, particularly NT-201, have received 
some approvals for cosmetic use in a few countries. Other 
injectable botulinum toxins, as well as a topical formulation, 
have been studied or are currently undergoing investigation 
in cosmetic and related indications.17–19
This review will examine these changes, will briefly 
examine the basic similarities and differences among avail-
able botulinum toxins, will summarize the key safety and 
efficacy data, and will discuss the implications for clinical 
practice.
The science of botulinum toxins: 
composition and pharmacology
Botulinum toxins occur in 7 known serotypes labeled A-G 
produced by different strains of Clostridium botulinum.20,21 
Clinically important biologic activity, particularly in the 
cosmetic arena, is limited primarily to the type A serotype, 
although a type B formulation is approved in several coun-
tries for treating cervical dystonia.21,22 Although botulinum 
toxin type B has been studied for cosmetic use, it generally 
elicits more pain upon injection and has been found to have 
a faster onset but shorter duration of action than the type A 
serotype.17,18,23–25 Therefore this review will be restricted to 
products containing botulinum toxin type A.
Similarities and differences among these botulinum toxins 
have been reviewed from preclinical and clinical perspec-
tives, and readers are referred to some of these publications 
Table 1 Comparisons among approved botulinum toxins
  OnabotulinumtoxinA AbobotulinumtoxinA NT -201
Company Allergan, Inc. Ipsen Inc./Medicis Inc. Merz Pharmaceuticals
Type Type A-Hall strain Type A-Hall strain Type A-Hall strain
Approvals (depend on specific 
indications)
In more than 75 countries 
worldwide, including United States  
and Canada
In more than 65 countries, 
including United States  
and Canada
Germany, other European countries, 
Mexico, Argentina, Brazil
Active substance (molecular 
weight)
Botulinum toxin type A complex 
(900 kDa)
Botulinum toxin type A 
complex (500 kDa)a
Botulinum toxin type A, free from 
complexing proteins (150 kDa)
Indications Blepharospasm; cervical 
dystonia; glabellar lines; hyperhidrosis
Blepharospasm; cervical 
dystonia; glabellar lines
Blepharospasm; cervical dystonia; 
cosmetic use in some countries
Mode of action SNAP-25 SNAP-25 SNAP-25
Units/vial 100 300 or 500 100
Notes: SNAP-25 (synaptosomal membrane-associated protein with the molecular mass of 25 kDa) = An intracellular protein that is essential for synaptic vesicle transmission; 
it has been identified as the molecular target of botulinum toxin type A. aThe formulation contains complexes of variable size between 500 kDa and 900 kDa.
Reproduced with permission from Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Therapy Lett. 2008;13(6):1–4.22Clinical Interventions in Aging 2010:5 103
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for additional, detailed, information.22,26–35 Basic properties 
of each product are summarized in Table 1.22 All botulinum 
toxins ultimately inhibit the release of acetylcholine from the 
neuromuscular junction and inhibit muscular contraction.27 
Type A botulinum toxins cleave a protein called synapto-
somal membrane-associated protein 25 kDa (SNAP-25). 
The active neurotoxin is 150 kDa, but the currently available 
formulations differ in their molecular weight because of the 
presence or absence of complexing proteins. The nontoxin 
proteins of the two forms of botulinum toxin type A approved 
in the United States for aesthetic indications each include a 
hemagglutinin.20 The two nonproprietary names for the cur-
rently FDA approved botulinum toxin type A products are 
onabotulinumtoxinA and abobotulinumtoxinA.
It has been suggested that the specific properties of each 
botulinum toxin may account in part for observed differ-
ences in clinical performance. For example, preclinical data 
indicate that the 500 kDa and 900 kDa have nonparallel 
dose-responsive curves, which means that their relative 
performance is not consistent across a range of dose ratios 
and that a given unit of one toxin does not stand in a con-
stant unit relationship to another toxin.36 Clinically, some 
investigators have observed differences in migration patterns 
for the two products, although others have taken issue with 
these findings.37–39
It is likely that differences among products in these studies 
are influenced by the specific dose ratios used.40 In this study 
the field of effectiveness in the frontalis muscles at 28 and 
112 days after injection of 2 botulinum toxin type As at 2-
dose ratios, abobotulinumtoxinA and onabotulinumtoxinA 
did not differ with respect to any effects at a dose ratio of 
2:1 (abobotulinumtoxinA:onabotulinumtoxinA). At a dose 
ratio of 2.5:1, however, the effect of abobotulinumtoxinA 
was more widespread (field of effectiveness) than was that of 
onabotulinumtoxinA. The data overall confirm that formula-
tions of botulinum toxins are not interchangeable, nor can 
they be converted by a single dose conversion factor.
Data on formulations without complexing proteins have 
not been published in this context at this point. It has also 
been suggested that differences in the amount of nontoxin 
protein could contribute to differences in the likelihood of 
immunogenic reactions, but thus far, clinical data are lacking. 
Virtually no antibody formation nor loss of efficacy has been 
found in cosmetic studies with botulinum toxin type A.41,42 The 
most important point regarding the differences in botulinum 
toxin formulations is that clinicians must understand that botu-
linum toxins are not identical because of an array of factors, 
and are therefore not interchangeable. Thus, it is essential to 
understand the properties and clinical performance of each 
product in order to achieve safe and satisfactory outcomes.
Distinguishing among botulinum 
toxins: revised labeling from  
the FDA
In response to reports of some serious adverse events (SAEs), 
the FDA announced label changes for all botulinum toxins in 
April 2009, which resulted in the addition of a boxed warn-
ing to call attention to the possibility that treatment with a 
botulinum toxin has the potential to cause symptoms similar 
to those of botulism.
Notably, the press release issued by the FDA stated that 
symptoms have mostly been reported in children with cerebral 
palsy who have been treated for muscle spasticity, an unap-
proved use. The release also emphasized that the action was 
taken “because of the potential for serious risks associated 
with the lack of interchangeability among the three licensed 
botulinum toxin products.”16 In addition, the FDA mandated 
a Risk Evaluation and Mitigation Strategy (REMS) to help 
clinicians understand risks and benefits, and to communicate 
these to their patients43 for all botulinum products. Prescrib-
ing information now includes an approved Medication Guide 
for patients.44
These additional changes to botulinum toxin product 
labeling have underscored how important it is to recognize 
that toxins are not interchangeable, and to incorporate this 
consideration into practice. Previous product labeling for 
botulinum toxins stated that formulations are not interchange-
able because of differences in assays, laboratory protocols, 
and specifics of the manufacturing processes. Nevertheless, 
the original nonproprietary (established) named products 
were derived from a single serotype, such as botulinum 
type A, failed to distinguish among the products. Subsequent 
to the announcement of the labeling changes noted above, 
the FDA also issued changes to the established names for 
4 products licensed in the United States (Table 2).43 Taken 
together, these changes indicate clearly that clinicians must 
develop expertise with each product they choose to use, and 
determine its optimal use in their individual practices even 
though each has been designated as safe and effective for 
the approved indications.
Safety and efficacy – from clinical 
trials to clinical experience
Since the effects of botulinum toxin type A on glabellar 
lines were first appreciated, safety and efficacy have been Clinical Interventions in Aging 2010:5 104
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supported and documented by numerous studies as well as 
extensive clinical experience. As an overview, virtually all 
large-scale studies, documenting safety and efficacy, are 
placebo-controlled, but are noncomparative. The primary 
efficacy endpoint for the majority of clinical studies has 
been based on changes on a 4-point scale of wrinkle severity 
(0 = none, 1 = mild, 2 = moderate, 3 = severe), sometimes 
termed the Facial Wrinkle Scale.42,45 Typically, responders 
are those who are rated as 0 or 1 posttreatment as evaluated 
by an investigator, trained observer, or independent assessor. 
Unless noted otherwise, responder rates presented herein will 
be the proportion of subjects rated by investigators as none 
or mild at maximum frown. Trials have also included inves-
tigator- and subject-assessed global improvement, duration 
of response, subject satisfaction, and other patient-reported 
outcomes (PROs), which will be reviewed briefly in separate 
sections. Note that onset of action cannot be derived from 
any of the pivotal studies because they were not designed 
to do so, and the earliest assessment times were at 7 days 
with onabotulinumtoxinA45 and 14 days with abobotulinum-
toxinA.42 Older data on onabotulinumtoxinA indicate that 
response onset with onabotulinumtoxinA is within the first 
24 to 72 hours,46 which is consistent with its product label-
ing regarding chemical denervation of injected muscles.45 
A number of studies, reports, and consensus publications 
have also helped refine dosing and techniques and establish 
guidelines for optimizing results.
Primary safety and efficacy studies
FDA regulatory approvals of onabotulinumtoxinA and 
abobotulinumtoxinA were based on well-controlled studies 
in the treatment of moderate to severe glabellar lines.42,45 
To the authors’ knowledge, another botulinum toxin type A 
formulated without complexing proteins has not been studied 
systematically in cosmetic indications. A report based on 
clinical experience suggests that it is active for these uses, 
but controlled clinical trials remain to be reported.47 Despite 
the addition of the previously cited warning to the prescribing 
information of all botulinum toxins approved in the United 
States, the use of these substances worldwide in facial aes-
thetics is associated with a remarkable record of safety and 
tolerability when used as indicated by fully qualified, well-
trained clinicians. Not only do clinical studies report that 
AEs are typically transient and mild to moderate in severity, 
vast clinical experience and the increase in the number of 
procedures performed annually is highly confirmatory. It 
would be beyond the scope of this article to evaluate safety 
in all published articles on botulinum toxins, and therefore 
only the results of registration trials and selected long-term 
studies for the 2 major formulations of botulinum toxin 
type A are presented.
Safety based on registration trials 
in the United States
OnabotulinumtoxinA was approved in 2002 by the FDA to 
temporarily improve the appearance of moderate to severe 
glabellar lines in adult patients aged 18 to 65 years on 
the basis of 2 placebo-controlled, randomized clinical tri-
als.15,41,42,45 Subjects (N = 537) had to have glabellar lines of 
at least moderate severity at maximum frown to be eligible.41 
They received either 20 U of onabotulinumtoxinA (n = 405) 
or an equal volume of placebo (n = 132) distributed equally 
among 5 injection sites. Most of the subjects were Caucasian 
(84%) females (82%). Because the 2 trials were identical in 
design, results were pooled and presented in their entirety 
along with an 8-month open-label extension.41,45
Treatment-related AEs declined with successive 
  treatments (Table 3).41 The 2 most frequently occurring, treat-
ment-related AEs, headache and blepharoptosis, diminished 
to less than 1% after the third treatment. The investigators 
suggested that this change could have resulted from improved 
injection skill, better understanding of the specifics of treating 
an individual patient, or the possibility of tolerance develop-
ment. Subjects who received 3 injections of onabotulinum-
toxinA were also tested for neutralizing antibodies. None 
of these patients tested positive for neutralizing antibodies. 
Although 4 subjects had positive tests after one of their 
treatments, all had negative tests after 1 year of treatment 
and remained responders.
Table 2 New and old drug names for botulinum toxins in the 
United States; tradenames have not changed43
New drug name Old drug name Indication(s)
OnabotulinumtoxinA Botulinum toxin 
type A
Cervical dystonia, 
severe primary axillary 
hyperhidrosis, strabis-
mus, blepharospasm; 
temporary improve-
ment in the appearance 
of moderate to severe 
glabellar lines
AbobotulinumtoxinA Botulinum toxin 
type A
Cervical dystonia, 
temporary improve-
ment in the appearance 
of moderate to severe 
glabellar lines
RimabotulinumtoxinB  Botulinum toxin 
type B
Cervical dystonia Clinical Interventions in Aging 2010:5 105
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In 2009, the FDA approved abobotulinumtoxinA to 
temporarily improve the appearance of moderate to severe 
glabellar lines (also based on the 4-point wrinkle severity 
scale) in adult patients younger than 65 years of age on the 
basis of 3 double-blind randomized studies, with a total of 
600 subjects.42,43 In each trial, subjects received 50 U of 
abobotulinumtoxinA, based on results from previous studies 
which indicated this to be the optimal dose.48,49
Like onabotulinumtoxinA, abobotulinumtoxinA was well 
tolerated in clinical studies.42 The safety population for which 
AEs were reported comprised 894 subjects (abobotulinum-
toxinA, 398; placebo, 496). Some of these subjects may have 
received both active treatment as well as placebo at different 
periods of study. Low rates of eye disorders, including pto-
sis (2% in active treatment, 1% placebo) occurred, did not 
increase with treatment, and were generally mild to moderate 
in severity, resolving over several weeks.42 The development 
of neutralizing antibodies was also low. It was reported 
that 1554 of subjects in the entire safety database received 
up to 9 cycles of treatments, and only 3 tested positive for 
antibodies posttreatment.42
Longer-term safety with repeated treatments
Extensive clinical experience indicates botulinum toxin used 
for facial aesthetic treatment to be safe and well tolerated over 
the long term. Several studies have reported safety profiles 
over repeated treatments or over the longer term in clinical 
practice. A retrospective single center analysis provided data 
on 853 treatment sessions in 50 patients treated with onabotu-
linumtoxinA (median dose, 40 U).50 Patients were required 
to undergo a minimum of 10 treatments (range 10–30). The 
time period between the first and last treatments ranged from 
nearly 3 years to approximately 9 years. More than 50% of 
the sessions involved treatment of more than one upper facial 
area, although treatment of the glabellar area predominated. 
The median interval between treatments was 17 weeks. Of 
all the treatments, 99% did not result in any AEs. Altogether, 
8 of the 50 subjects experienced 10 AEs. Of the 10 events, 5 
were deemed treatment-related: bilateral eyebrow ptosis (2); 
right brow ptosis (1); right eyelid ptosis (1); and dysphagia 
(1). All were mild in severity and transient. The incidence of 
ptosis was approximately 0.47%/session.
A repeated treatment study of up to 5 cycles was con-
ducted in Japanese subjects.51 Subjects received either 10 U 
(n = 180) or 20 U (n = 183) of onabotulinumtoxinA. They 
could be retreated at the same dose only if at least 12 weeks 
had elapsed and if glabellar line severity had returned to 
at least moderate. Responder rates did not diminish over 
treatment cycles, nor did any blood samples yield a positive 
test for neutralizing antibodies. Blepharoptosis occurred in 
3.9% of subjects with no significant differences between 
treatment groups for this or any other AE deemed to be 
drug related.
A retrospective chart review was also undertaken in 
945 abobotulinumtoxinA-treated patients treated over 3 to 
5 consecutive cycles.52 Glabellar lines were treated in the 
vast majority of sessions, although most patients received 
treatment of multiple upper facial areas. The median total 
dose/session was 100 U. Approximately 91% of patients 
experienced no AEs. A total of 16 patients experienced 19 
instances of lid or brow ptosis (0.51%/treatment cycle for 
patients receiving glabellar and/or frontalis treatments). 
These excellent safety results are thus comparable to those 
with onabotulinumtoxinA.
Table 3 Incidence of the most commona (1% in any treatment cycle) treatment-related AEs by treatment cycle with onabotulinum-
toxinA
Adverse event, % First botulinum toxin (n = 501) Second botulinum toxin (n = 362) Third botulinum toxin (n = 258)
Headache 8.2 0.6 0.8
Blepharoptosis 3.0 2.2 0.8
Face pain 1.8 0.0 0.0
Edema at injection site 1.4 0.8 0.4
Pain at injection site 1.4 0.8 0.0
Nausea 1.2 0.0 0.0
Ecchymosis 1.2 0.0 0.0
Muscle weakness 1.4 0.3 0.0
Erythema 1.6 0.0 0.0
aIncidence 1% in any treatment cycle.
Carruthers A, Carruthers J, Lowe NJ, et al; for the BOTOX® Glabellar Lines I and II Study Groups. One-year, randomised, multicenter, two-period study of the safety and efficacy 
of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res. 2004;7:1–20.41 © 2004 Informa Healthcare. Reproduced with permission.Clinical Interventions in Aging 2010:5 106
De Boulle et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Recently, interim safety results of an open-label exten-
sion trial using 6 repeated treatments of abobotulinumtoxinA 
for moderate to severe glabellar lines over 17 months with 
a minimum of 85-day intervals were reported.53 Of the 
768 subjects, 2259 treatments had taken place, with 63% of 
subjects receiving up to 3 injections. At the time of analysis, 
0.9% of subjects had received 6 treatments. Treatment-
  emergent AEs decreased over cycles. In total, 10 subjects 
(1.3%) had 10 instances of ptosis in the 2259 treatments. 
The duration of these episodes was less than 3 weeks in 70% 
of the cases. Similar findings were reported for an analysis 
of 1200 subjects who had received up to 5 treatments within 
a 13-month period.54
Meta-analysis of onabotulinumtoxinA  
safety in global registration trials
In a recent study, the results of 6 randomized, double-blind, 
placebo-controlled trials and 3 open-label studies were 
subjected to a meta-analysis. Comprising 1678 subjects, the 
results confirmed the safety and tolerability of onabotulinum-
toxinA treatment for the glabellar and crow’s feet areas.55 
SAEs were generally mild to moderate in severity and in 
line with the expected AEs for this product. Importantly, no 
SAEs were detected, nor did any new, treatment-related AEs 
emerge. Taken together, the results demonstrate that these 2 
formulations of botulinum toxin type A, onabotulinumtoxinA 
and abobotulinumtoxinA, are safe and well tolerated based 
on both shorter- and longer-term studies.
Efficacy with onabotulinumtoxinA
In the pooled pivotal trials of onabotulinumtoxinA con-
ducted in 537 subjects, the primary efficacy endpoints 
were the investigator’s rating of glabellar line severity and 
the subject’s global assessment of change in appearance 
at day 30 posttreatment. According to investigator ratings, 
the peak responder rate of 80% was observed at day 30, 
but 25% of subjects remained classified as responders at 
day 120 (Figure 1a).45 Subject ratings followed a similar 
pattern with an 89% subject-rated responder rate at day 
30 and 39% at day 120 (Figure 1b).45 Subjects were able to 
receive a second, open-label treatment after completing the 
blinded study period of 120 days. A third injection option 
was also available, and 258 subjects received all 3 treat-
ments. The proportion of responders at maximum frown 
was significantly higher after the second and third treat-
ments than at the same time point after the first treatment 
(Figure 2).41
Efficacy with abobotulinumtoxinA
In the abobotulinumtoxinA trials, treatment success was evalu-
ated at day 30 and was defined as glabellar line severity of none 
or mild at maximum frown, with at least a 2-grade improve-
ment from baseline in the combined assessments of investi-
gators and subjects.42 Treatment success ranged from 55% to 
60% with abobotulinumtoxinA (n = 376) compared to 0% with 
placebo (n = 224) across the 3 studies. In addition, percentages 
of subjects achieving investigator- or subject-assessed ratings 
of none or mild at each posttreatment follow-up visit were also 
presented for each study (Figure 3).56 These results are similar 
to those seen with onabotulinumtoxinA, although it is obvi-
ously not possible to compare directly between studies.
Additional clinical studies
OnabotulinumtoxinA
A registration trial with onabotulinumtoxinA treatment of 
glabellar lines in Japanese subjects was also conducted.57 
In this study, 140 subjects with moderate to severe glabel-
lar lines at baseline were treated with either 10 U (n = 45) 
onabotulinumtoxinA, 20 U (n = 46) onabotulinumtoxinA, or 
placebo (n = 49). The percentage of responders (rated none 
or mild) ranged from 82% and 89% at week 1 to 24% to 32% 
at week 16 for the 10-U and 20-U doses, respectively. Peak 
responses occurred at week 4 with 86% and 89% of subjects 
in the two groups rated as responders. Each dose differed 
significantly from placebo, but not from each other at each 
time point although the 20-U dose was consistently associated 
with slightly higher responder rates. In a repeated treatment 
study of a similar population, 363 subjects received up to 5 
treatments with onabotulinumtoxinA.51 Peak responder rates 
ranged from 92% to 99% at the week 4 evaluation of each 
of the 5 possible treatment cycles, indicating no diminution 
of efficacy over the 64 weeks of this trial.51
Consistent with clinical experience, dose-ranging studies 
established that males typically require higher doses than 
females of onabotulinumtoxinA, owing to their typically 
greater muscle mass.58,59 For males (N = 80, 20/group), 
the peak responder rate occurred between weeks 2 and 4 
posttreatment and was 65% in the 20-U group compared to 
100% in the other groups (40 U, 60 U, 80 U).58 Generally, 
the higher the dose, the longer the duration of the response, 
with a mean time to relapse (return to baseline severity on 
2 consecutive visits, 30 days apart) of 24.2 weeks for the 80-U 
dose compared to 17.6 weeks for the 20-U dose.
In a similar study in females, subjects (N = 80, 20/group) 
received onabotulinumtoxinA doses of 10, 20, 30, or 40 U to 
their moderate to severe glabellar lines.59 The 10-U dose was Clinical Interventions in Aging 2010:5 107
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Figure 1 Responder rates at each follow-up visit after treatment with onabotulinumtoxinA during the double-blind period of the study.45 A) Physician’s ratings of glabellar line 
severity at maximum frown. Responder rates were the percentage of subjects with ratings of none or mild. B) Subject’s assessment of changes in the appearance of glabellar 
lines. Responder rates were the percentages of subjects with a least moderate improvement.
consistently less effective than the other doses. As is typical, 
peak responder rates occurred between weeks 2 and 4, and 
ranged from 85% in the 10-U group to 100% in the other 
treatment groups. The response rates with the higher doses 
did not differ significantly among each other. The duration of 
benefit was generally longer in the higher dosage groups.
Although response rate and response duration are 
associated with unit dose of onabotulinumtoxinA, dilution Clinical Interventions in Aging 2010:5 108
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does not appear to influence efficacy. In one study, a dose 
of 30 U of onabotulinumtoxinA was delivered at 7 sites 
in the glabellar in varying dilutions.60 At the 4 dilutions 
used (100, 33.3, 20, or 10 U/mL; N = 80, 20/group), 
no differences in responder rates were observed among 
groups despite differences in the volumes injected per site. 
Responder rates peaked at week 2 and ranged from 95% to 
100%. The majority of patients had relapsed by week 24, 
regardless of treatment group.
Two dosages, 20 U (n = 15) and 30 U (n = 16) of 
  onabotulinumtoxinA were examined in a small, randomized, 
controlled study with African American women (skin types IV 
and IV).61 Subjects were evaluated at days 30, 60, 90, and 120 
posttreatment. The peak response at day 30 was 92.4% for 
the 20-U treatment group and 100% for the 30-U group. No 
differences were observed between treatment groups, suggest-
ing that clinicians can select the appropriate dose based on an 
individual’s presentation. Although the vast majority of clinical 
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studies have been conducted primarily with Caucasian females, 
the results from this study demonstrate that onabotulinum-
toxinA is safe and effective for African American women.
AbobotulinumtoxinA
Three dosages (25, 50, or 75 U) of abobotulinumtoxinA 
and placebo were studied in 119 patients.48 The 25-U dose 
consistently resulted in lower responder rates than the other 
doses, although the percentage of responders differed from 
placebo through day 90, but not at day 180 posttreatment. 
Data at 120 days were not provided. Responder rates at day 14 
were 66% and 67% for the 50- and 75-U doses, respectively. 
Responder rates peaked at day 30 at 76% for the 2 higher 
doses. It appeared that the 75-U dose provided somewhat 
higher response rates overall, but differences between dosage 
groups were not analyzed. Each group differed significantly 
from placebo through day 90.
Another study with abobotulinumtoxinA compared 20, 
50, and 75 U injected in 5 sites of the glabellar area.49 Fol-
low-up in this study was through day 120. Although investi-
gator-assessed responder rates were not reported for all time 
points, it was noted that the proportion of responders with the 
20-U dose differed from placebo through day 90, whereas, 
the responder rates with the 50- and 75-U doses differed from 
placebo through day 120 posttreatment, at which time 26% 
and 27% respectively remained responders.
When 3 injections totaling 30 U of abobotulinumtoxinA 
was compared with 5 injections (50 U) in a 16-week study of 
221 subjects, responder rates at week 4 were approximately 
86% for each treatment group62 and differed significantly 
from placebo. Responder rates for the duration of the 
study were not explicitly reported, but subject satisfaction 
ratings declined as would be expected over the course of the 
study. Nevertheless 60% to 70% of subjects remained at least 
moderately satisfied at week 16. Efficacy was not affected by 
dose or number of injection sites in this study.
Based on standard clinical practice of adjusting dosing 
to muscle mass, investigators examined the results of varied 
dosing in male and female subjects (50, 60, 70, or 80 U).63 
The overall responder rate based on the blinded evaluator 
assessment at day 30 was 85%. Some differences by subgroup 
were noted: for example, the younger the age, the greater 
the responder rate; the more severe the lines, the lower the 
responder rate. The responder rate for females (87%) was 
higher than for males (65%), and African American sub-
jects had a slightly higher responder rate than Caucasians 
(89% vs 84%, respectively). Statistical analyses were not, 
however, provided for these subgroup analyses.
Comparative studies
To our knowledge, only one double-blind, randomized, 
controlled study compared onabotulinumtoxinA (20 U) and 
abobotulinumtoxinA (50 U) for the treatment of glabel-
lar lines.64 In this study, follow-up visits were conducted 
at weeks 2, 8, 12, and 16. The responder rate was defined 
as the proportion of subjects with an improvement from 
baseline of at least 1 grade in glabellar line severity on the 
4-point scale.42 The peak response was observed at 8 weeks 
posttreatment with 94% of onabotulinumtoxinA-treated 
subjects and 97% of abobotulinumtoxinA-treated subjects 
meeting the response criterion. At week 16, a statistically 
significant different proportion of subjects in each group 
(onabotulinumtoxinA: 53%; abobotulinumtoxinA: 28%) 
continued to show this level of improvement. The incidence 
of subjects with glabellar severity of none or mild was 45% 
(onabotulinumtoxinA) and 50% (abobotulinumtoxinA) at 
week 8, and at no time point was the difference between 
treatment groups statistically significant.
In considering these results, it is important to note that 
mean age of subjects differed significantly by treatment group 
and that the proportions with moderate and severe glabellar 
lines at baseline were not identical, although that difference 
was not statistically significant. In addition, responder rates 
were not presented for the 2-week follow-up evaluation, 
and subjects were not assessed at 4 weeks posttreatment, 
the typical primary efficacy endpoint adopted in the larger 
scale clinical trials.
Duration
A comprehensive review on duration of effect for treating 
various facial areas has recently been published.28 It was 
concluded that patients can generally expect botulinum toxin 
type A treatment of their glabellar lines to last at least 3 months 
and sometimes longer. The specific impact of age, baseline 
glabellar rhytid severity, sex, number of previous treatments, 
and the impact of combination with other modalities remains 
to be clarified. In addition, for any estimates to be accurate, the 
study must have followed subjects for a long enough interval 
to capture those potential long-term responders.
Estimated duration depends considerably on how it is 
measured. For example, some studies with the onabotu-
linumtoxinA formulation measured time to relapse based 
on a return to baseline glabellar severity at 2 consecutive 
visits (30 days apart).58,59 In these studies, the mean time to 
relapse ranged from approximately 18 weeks (20-U dose) 
to 24 weeks (80-U dose).58 The estimated mean duration in 
males was similar for doses ranging from 40 to 80 U.58Clinical Interventions in Aging 2010:5 110
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In the one comparative study of onabotulinumtoxinA and 
abobotulinumtoxinA, the estimated relapse rates at week 16 
were 23% and 40%, respectively.64 This finding, however, 
was not statistically significant. Nevertheless, based on all the 
data in the study, the investigators concluded that onabotu-
linumtoxinA affords a longer duration of efficacy.64
Duration can also be based on the proportion of respond-
ers over time. This measure provides information about the 
longest potential duration that may occur in a limited number 
of patients (if the study duration is sufficient). When these 
data are presented in a study, mean or median response time 
can be derived.
In a study designed to determine duration based on 
when the next injection was scheduled, results indicated the 
majority of patients treated with abobotulinumtoxinA were 
reinjected between months 3 and 4.65 In clinical practice, 
versus trials, it is likely that those patients seeking retreat-
ment will be influenced by a number of factors, such as 
appearance and cost. The impact of these factors will largely 
depend on the individual. For example, those who are most 
influenced by appearance may seek retreatment well before 
glabellar line severity has returned to baseline, whereas those 
for whom cost takes precedence are likely to wait somewhat 
longer before seeking retreatment. Based on available data, 
it appears that each product provides a range of duration, 
generally 3 to 5 months. In the absence of well-controlled 
comparative studies, it is not possible to determine how 
specific product properties interact with such other potential 
variables as baseline glabellar line severity, age, sex, ethnicity, 
and possibly injection techniques and patterns in duration.
In clinical practice, duration is also apt to be affected by 
numerous variables. As examples, patients may reschedule 
at the time of treatment and thus be retreated based on a fixed 
time, regardless of need; they may choose to be retreated 
before return to baseline to maintain a certain level of 
improvement in appearance. If they return to the office before 
return to baseline, dosing may be adjusted, which may affect 
subsequent response duration.
Satisfaction with treatment  
and other PROs
Patient satisfaction and other PROs comprise a number of 
outcome variables. Satisfaction with botulinum toxin treat-
ment has been included in several major clinical trials and 
has been the subject of a recent comprehensive review.29 
Most frequently, subjects rate their satisfaction on one of a 
number of categorical, Likert-type scales, such as the Facial 
Lines Treatment Satisfaction Questionnaire (FLTSQ), which 
ranges from “very dissatisfied” to “very satisfied”.66,67 Across 
the studies reviewed, subject satisfaction ratings ranged from 
at least 60% to 100% following treatment for glabellar lines 
(Table 4).29,48,58,62,64,65,67–70
The comparative study between onabotulinumtoxinA and 
abobotulinumtoxinA suggested that subjects were more satis-
fied with onabotulinumtoxinA treatment, but significant dif-
ferences were observed only at a single time point, week 16.71 
Another, open-label study found that patients treated with ona-
botulinumtoxinA and then switched to abobotulinumtoxinA 
rated their satisfaction to be higher with onabotulinumtoxinA 
treatment.72 Specifically, at a mean of 20 weeks posttreatment 
with onabotulinumtoxinA, 100% of patients rated themselves 
as satisfied or extremely satisfied. In contrast, 31% of abobo-
tulinumtoxinA-treatment patients rated themselves satisfied or 
extremely satisfied at a mean of 16 weeks posttreatment. The 
limitations of this study included the use of both retrospective 
and prospective data as well as the presence of other poten-
tially confounding variables. One such confounding variable 
is the impact that cognitive dissonance may have had upon 
PROs and satisfaction. This phenomenon is recognized, but 
has not been studied with onabotulinumtoxinA. This may be 
an applicable area of research in facial aesthetics.73 Neverthe-
less, these findings suggest that additional controlled trials are 
warranted to help clinicians understand how patients perceive 
their responses to treatment with various available products to 
understand how best to use each product.
A prospective open-label study using the FLTSQ asked 
onabotulinumtoxinA-treated subjects to rate their satisfac-
tion with the effects of treatment, with the experience of the 
procedure, and their overall treatment.67 At days 30 and 120 
posttreatment, subject satisfaction was high; 95% of subjects 
were satisfied overall at day 30, and 86% remained satisfied 
at day 120; 88% and 82% were satisfied with the treatment 
effects at days 30 and 120, respectively, and 93% and 95% 
were satisfied with the experience at days 30 and 120, respec-
tively. Moreover, 88% (day 30) and 82% (day 120) of subjects 
reported satisfaction on individual items comprising the 
Effects of Treatment domain of the FLTSQ. These included 
aspects of appearance and feelings about appearance.
Other PROs
In addition to measuring satisfaction, investigators have 
recently begun to assess other outcomes deemed to be of 
importance to patients seeking aesthetic treatments. For 
example, the FLO questionnaire was developed to assess 
such specific outcomes as self-perception of age, perception 
of attractiveness, and the extent to which facial lines result in Clinical Interventions in Aging 2010:5 111
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looking tired, stressed, or angry when that does not coincide 
with the way the patient feels.74,75 The FLO questionnaire has 
been used to assess the effect of onabotulinumtoxinA treat-
ment on multiple upper facial line areas, as well as moderate 
to severe glabellar lines alone.75,76
The glabellar-specific FLO questionnaire (7 items, 
FLO-7) was used to evaluate PROs in subjects with moderate 
to severe glabellar lines.76 The study included a Self-Percep-
tion of Age (SPA) item. Subjects randomly assigned to receive 
either onabotulinumtoxinA (n = 35) or placebo (n = 35) were 
Table 4 Selected studies on subject satisfaction with botulinum toxin treatmenta
First author Treatment RCT 
(Y/N)
No of 
patients 
(total)
Scale Selected 
data
1 month 3 or 4 months Other time 
points
Assessment 
time point 
not specified
OnabotulinumtoxinA glabellar studies
Stotland67 Onabotulinum- 
toxinA
N 58 Satisfaction 
(14 items, 
7 points; 
FLTSQ)
Percentage 
somewhat 
satisfied, 
satisfied, 
or very 
satisfied
20 U: 95% 
(Overall), 88% 
(treatment 
effects), 95% 
(procedure)
20 U: 86% 
(Overall), 
8 (treatment 
effects), 
93% 
(procedure)
Beer68 Onabotulinum- 
toxinA
Y 77 Satisfaction 
(5 categories)
Percentage 
satisfied 
or very 
satisfied
20 U: 71.4% 20 U: 83.4%
Carruthers58 Onabotulinum- 
toxinA
Y 80 Satisfaction 
(not 
stated)
Percentage 
satisfied 
or very 
satisfied
20 U: 66% 
30 U: 70% 
40 U: 79%
Grimes69 Onabotulinum- 
toxinA
Y 31 Satisfaction 
(5 points)
Percentage 
satisfied 
or very 
satisfied
20 U/30 U: 
100%
20 U/30 U: 60%
Ellis70 Onabotulinum- 
toxinA
N 15 Satisfaction 
(5 points)
Mean score; 
5 is most 
satisfactory
4 (7–10 days); 
individualized 
dosing
AbobotulinumtoxinA glabellar studies
Ascher65 Abobotulinum-
toxinA
Y 100 Satisfaction 
(4 points)
Percentage 
satisfied 
or very 
satisfied
50 U: 78% 3 months: 73.5% 
4 months: 75.0%
Rzany62 Abobotulinum-
toxinA
Y 221 Satisfaction 
(4 points)
Percentage 
satisfied 
or very 
satisfied
30 U: 32.3% 
50 U: 43.9%
Ascher48 Abobotulinum-
toxinA
Y 119 Satisfaction 
(4 points)
Percentage 
satisfied 
or very 
satisfied
25 U: 65.5% 
50 U: 86.2% 
75 U: 75.8%
25 U: 82.1% 
50 U: 72.4% 
75 U: 72.4%
6 months; 
25 U: 68.9% 
50 U: 93.1%
75 U: 62.0%
Comparative glabellar study
Lowe64 Onabotulinum- 
toxinA vs 
abobotulinum-
toxinA
Y 30 Satisfaction 
(7 points)
Mean score; 
7 was most 
satisfactory
20 U: Onabotulinum- 
toxinA: 3.8; 
50 U: Abobotulinum-
toxinA: 2.7
aPlacebo or comparative agent data are not presented for the purposes of this table. Botulinum toxin type A treatments consistently differed statistically from placebo or 
comparative agents.
Please refer to individual studies.
Adapted with permission from Fagien S, Carruthers JDA. A comprehensive review of patient-reported satisfaction with botulinum toxin type A for aesthetic procedures. Plast 
Reconstr Surg. 2008;122(6):1915–1925.29 Copyright © 2008 Wolters Kluwer Health.
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evaluated at 4 weeks posttreatment for the double-blind 
phase of the study. At that time, subjects whose glabellar 
lines remained moderate to severe were offered open-label 
treatment with onabotulinumtoxinA.
At the 4-week evaluation, subjects treated with ona-
botulinumtoxinA for mild to moderate glabellar lines 
reported looking a mean of 4 years younger than at base-
line. Placebo-treated subjects reported no changes, and the 
differences between groups was statistically significant.76 
Statistically significant changes (P = 0.01) in self-percep-
tions of age were maintained through the 12 weeks of the 
study in the subjects initially treated with onabotulinum-
toxinA. Similarly, onabotulinumtoxinA-treated subjects 
exhibited significant improvements on the FLO-7 at 4 weeks 
posttreatment (Figure 4).76 Responder rates in this study were 
consistent with those of other major clinical trials: 85% of 
subjects were deemed responders by investigators at week 
4, 86% at week 8, and 67% at week 12. The results of these 
studies demonstrate that onabotulinumtoxinA treatment pro-
vides efficacy as traditionally assessed by so-called objective 
measures in randomized controlled trials (ie, wrinkle severity 
on a 4-point scale), but also as evaluated by endpoints that 
are likely to be most important to how patients look and feel 
about themselves.
PROs and treatment continuation
Adherence refers to patients’ persistence with a therapeutic 
regimen. In aesthetic medicine, this concept is reflected in 
the choices our patients make about continuing with a treat-
ment plan and in their selection of specific products and 
procedures. It is important to understand the factors and 
considerations that contribute to our patients’ willingness to 
return for treatment and even their readiness to recommend 
treatment to their friends. It can be hypothesized that adher-
ence to a treatment regimen would be strongly influenced by 
our patients’ satisfaction with their outcomes.
One of the earlier studies that evaluated patient satis-
faction, included attitudes on beauty and body, treatment 
outcome satisfactions, and general quality of life.77 Thirty 
patients who had received onabotulinumtoxinA treatment for 
upper facial lines (primarily glabellar) within the previous 
3 months were surveyed on patients attitudes on beauty and 
body using scales of the Freiburg Questionnaire on Aesthetic 
Dermatology and Cosmetic Surgery (FQAD) and the Freiburg 
Life Quality Assessment core (FLQA-C) version. More than 
80% reported that treatment with onabotulinumtoxinA was 
beneficial, and 100% of the patients would recommend it 
(Figure 5).77 Patients also reported feeling more attractive 
and more comfortable with their bodies (Table 5).77
100
90
80
70
60
50
40
30
20
10
0
Baseline
35
32
35
64
59 59
P < 0.001
Week 4 Week 8 Week 12
Placebo (n = 35)
OnabotulinumtoxinA
(n = 35)
M
e
a
n
 
F
L
O
-
7
 
S
c
o
r
e
Figure 4 Mean FLO scores after onabotulinumtoxinA or placebo treatment in subjects with moderate to severe glabellar lines. The double-blind phase of the study was 
4 weeks in duration, but subjects were followed for 12 weeks.
Reprinted with permission from Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: 
a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33(1 Spec No):S2–S9.76 © John Wiley & Sons Inc; 2007.
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The probability that a patient will continue with a treat-
ment plan is likely to be based on other factors in addition to 
their reported satisfaction. Optimal outcomes are ultimately 
the result of an interaction of patients, physician, and practice 
attributes.
Ensuring optimal outcomes
A clinician’s responsibility is to understand each patient’s 
unique needs, goals, and expectations, and to establish realistic 
expectations. This has been duly stressed in many published 
studies and consensus recommendations.78,79 Certainly, all 
clinicians have encountered potential patients who are not 
acceptable candidates for specific aesthetic procedures, 
whether because of medical or psychological factors. As the 
field of aesthetic medicine has continued to evolve, knowledge 
about ways to increase the likelihood of optimal outcomes in 
appropriate candidates has continued to progress.
Achieving a harmonious, balanced look
For example, the principles of facial rejuvenation have 
come to embrace a more natural, relaxed look.79 One con-
sequence is the use of lower doses of onabotulinumtoxinA 
to treat certain facial areas such as the forehead.79 Another 
is the recognition that facial areas ought not to be treated 
in isolation, but as a part of an overall aesthetic treatment 
plan. One placebo-controlled study (N = 40) demonstrated 
that treating multiple upper facial lines (glabellar, forehead, 
crow’s feet) with onabotulinumtoxinA (64 U in 16 sites;) was 
both effective and well tolerated.75 Responder rates at week 4 
for each facial area were 100% at both repose and maximal 
contraction, with the exception of the crow’s feet at maximal 
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Figure 5 Patients’ reactions to treatment with onabotulinumtoxinA (N = 30).
Reprinted with permission from Sommer B, Zschocke I, Bergfeld D, Sattler G, Augustin M. Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. 
Dermatol Surg. 2003;29(5):456–460.77 © John Wiley & Sons Inc, 2003.
Table 5 Patient satisfaction with onabotulinumtoxinA treatment 
as assessed by items on the FQAD (N = 30)
Answer OnabotulinumtoxinA, %
I recommend the treatment 100.0
The treatment was beneficial to me 80.0
I was stressed by treatment 0.0
I feel more attractive 55.1
I feel more comfortable with my body 76.7
My emotional well-being is better 30.0
I have more confidence in my appearance 44.8
I can profit from the treatment in my job 20.6
I don’t like to tell others about 
the treatment
13.3 
Reprinted with permission from Sommer B, Zschocke I, Bergfeld D, Sattler G, 
Augustin M. Satisfaction of patients after treatment with botulinum toxin for dynamic 
facial lines. Dermatol Surg. 2003;29(5):456–460.77 © John Wiley & Sons Inc, 2003.Clinical Interventions in Aging 2010:5 114
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contraction (85%). In addition, scores on the FLO-7 improved 
significantly at week 4 and were maintained throughout the 
12-week trial. AEs were mild and transient, and ptosis did 
not occur in this study. Probable treatment-related AEs dur-
ing the double-blind phase included one instance of tightness 
across the forehead and one instance of pulling lines at the 
outer eyelid (20 subjects total).75
Treating multiple upper facial lines, in contrast to 
the glabellar alone, may result in a greater magnitude of 
improvement.75,76 Although a direct comparison has not been 
undertaken in a trial, it is interesting to consider the results 
of the 2 studies that used the FLO questionnaire to evaluate 
PROs.75,76 With the exception of the number of sites injected 
and the total number of onabotulinumtoxinA units per sub-
ject, the study protocols were identical. Figure 6 illustrates 
the improvement in FLO scores at week 4 from each study.75,76 
Note that baseline scores on the FLO were identical within 
and between studies. Treating multiple facial areas coincides 
with much of current clinical practice.
Combining modalities
Another approach to optimizing outcomes is the use of 
minimally invasive modalities in combination. Botulinum 
toxin has long been considered the foundation of treatments 
for the upper face, whereas fillers are the preferred method 
of treating the lower face.79 As techniques and products have 
evolved, it has become clear that combinations afford excel-
lent and safe results, while addressing the multidimensional 
characteristics of facial aging. This approach was addressed 
in detail in a recent consensus publication on the use of 
botulinum toxins and hyaluronic acids.79
In subjects with severe glabellar rhytids, subjects who 
received onabotulinumtoxinA (30 U) as well as nonani-
mal, stabilized, hyaluronic acid (NASHA) experienced a 
substantially prolonged outcome.80 Specifically the median 
time to baseline furrow severity was 18 weeks in the group 
treated with NASHA compared with 32 weeks for the group 
receiving onabotulinumtoxinA plus NASHA. Combination 
treatment did not increase the incidence of AEs.
Other studies have demonstrated the safety and efficacy of 
onabotulinumtoxinA in combination with any of a number of 
modalities including collagen, intense pulsed light, and laser 
resurfacing.81–86 Consistently, combination therapy provides 
subjects with additional benefits versus monotherapy. The 
effects of abobotulinumtoxinA in combination with other 
aesthetic modalities remain to be evaluated.
Another aspect of achieving optimal outcomes is to 
tailor treatment to each individual. Typically, clinical trials 
of botulinum toxins utilize fixed dosing regimens. A recent 
study with abobotulinumtoxinA allowed variable dosing 
within the range of 50 to 70 U in females and 40 to 80 U 
in males, depending on investigator-assessed mass of the 
corrugators and procerus muscles.63 Doses of abobotu-
linumtoxinA were well tolerated and resulted in responder 
rates typical of fixed dose studies. The results confirmed the 
utility of adjusting dosing to clinical presentation, which is 
typical of clinical practice. The design of the study, however, 
did not include assessment of PROs, including satisfaction, 
nor was standardized dosing compared directly with vari-
able dosing based on muscle mass and gender. Nevertheless, 
the results indicate that doses can be increased as needed 
without sacrificing tolerability. The dose-ranging studies 
conducted with onabotulinumtoxinA in males and females 
also demonstrated that increasing the dose within the ranges 
studied did not increase the incidence of AEs.58,59
Avoiding complications
Beyond an in-depth understanding of facial anatomy and 
physiology, clinicians must thoroughly understand the prop-
erties of each product they use in their practices because, as 
discussed, each is unique. Specific potential complications 
and how to avoid them have been reviewed extensively, par-
ticularly for the onabotulinumtoxinA formulation because of 
its longer history of research and use.78,79,87,88 The vast major-
ity of complications are mild and transient.87 More serious or 
unwanted effects such as ptosis can often be traced to lack 
of experience or poor technique and subsequent diffusion 
to adjacent musculature from the site of injections. Because 
formulations may differ in their diffusion characteristics, 
a subject of some lively discussion, it is essential that clini-
cians become completely familiar with the performance of 
any specific product in their own hands.37,39
Summary and conclusions
The advent of botulinum toxin use for the treatment of 
glabellar lines heralded a new era in aesthetic medicine 
and an unparalleled growth in the annual number of pro-
cedures over the decade from 1997 to 2007.89,90 In the 
United States alone, nearly 2.5 million botulinum toxin 
procedures were performed in 2008 and were attributed 
to the onabotulinumtoxinA formulation.89 The approval of 
another botulinum type A formulation, abobotulinumtoxinA, 
may be expected to spur competition and additional usage. 
With FDA approval of this formulation for the treatment of 
  glabellar lines has come a new warning, generated primarily 
by concerns for safety in therapeutic, in contrast to cosmetic, Clinical Interventions in Aging 2010:5 115
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indications. Nevertheless, this is an important reminder that 
all medical procedures and products carry unique benefit:risk 
profiles. Not only must clinicians be thoroughly familiar with 
these, they must be able to educate their patients as well as 
establish realistic expectations.
One of the important changes that has come about with 
the new product labeling for botulinum toxins approved for 
use in the United States is the adoption of new established 
(nonproprietary) names. The name changes underscore that 
even with a given serotype, such as botulinum toxin type A, 
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Figure 6 Improvements in FLO scores in 2 studies following treatment with onabotulinumtoxinA.
A) Reprinted with permission from Carruthers J, Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg. 
2007;33(1 Spec No):S10–S17.75 © John Wiley & Sons Inc; 2007. B) Reprinted with permission from Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported 
outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33(1 Spec No):S2–S9.76 © John 
Wiley & Sons Inc; 2007.Clinical Interventions in Aging 2010:5 116
De Boulle et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
formulations are not interchangeable. This labeling change 
should not surprise experienced clinicians, who may have 
observed differences in the clinical performance of available 
products. The recognition that biologic agents derived from 
similar sources are not necessarily biosimilar is also consistent 
with findings on other aesthetic products, such as hyaluronic 
acid fillers, as well as with other therapeutic categories. This 
means that clinicians cannot apply techniques and dosing from 
one formulation to another, but must rather learn how to use 
each product properly to provide optimal and safe outcomes for 
their patients. As in other medical settings, clinicians perform a 
thorough pretreatment assessment followed by the development 
of a comprehensive, individualized treatment plan that includes 
the most appropriate products and procedures, ongoing assess-
ment, and modification of the plan as needed. Because of the 
lack of head-to-head studies between available products, much 
research is still required to provide more information on how 
formulations perform with respect to all outcomes, including 
satisfaction and other important patient-reported endpoints.
As more about the bidirectional effects of facial expres-
sion is learned – influencing mood, psychological state, 
self-perception, and perception by others, it is anticipated 
that botulinum toxin type A will continue to play a pivotal 
role in facial aesthetics and rejuvenation, whether used alone 
or in combination with other modalities. Although botuli-
num toxin type A remains the cornerstone of upper facial 
  treatment, clinicians in aesthetic medicine have come to 
understand that patients deserve a full facial aesthetic evalu-
ation with the treatments selected based on their individual 
goals and desires. Within this context, additional informa-
tion to help patients make informed decisions on choice of 
products and procedures can be offered.
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